BRPI0613358A8 - ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência - Google Patents

ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência

Info

Publication number
BRPI0613358A8
BRPI0613358A8 BRPI0613358A BRPI0613358A BRPI0613358A8 BR PI0613358 A8 BRPI0613358 A8 BR PI0613358A8 BR PI0613358 A BRPI0613358 A BR PI0613358A BR PI0613358 A BRPI0613358 A BR PI0613358A BR PI0613358 A8 BRPI0613358 A8 BR PI0613358A8
Authority
BR
Brazil
Prior art keywords
dementia
treatment
conditions related
fat acids
polyunsaturated fat
Prior art date
Application number
BRPI0613358A
Other languages
English (en)
Inventor
A Ellis Lorie
Original Assignee
Dsm Ip Assets Bv
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv, Martek Biosciences Corp filed Critical Dsm Ip Assets Bv
Publication of BRPI0613358A2 publication Critical patent/BRPI0613358A2/pt
Publication of BRPI0613358A8 publication Critical patent/BRPI0613358A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ácidos graxos poliinsaturados para o tratamento da demência e condições relacionadas à pré-demência. as composições e métodos para tratamento ou prevenção de demência ou pré-demência relacionada às condições e/ou sintomas ou características de tais condições estão expostas.
BRPI0613358A 2005-07-08 2006-07-07 ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência BRPI0613358A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69791105P 2005-07-08 2005-07-08
US60/697,911 2005-07-08
US77914506P 2006-03-02 2006-03-02
US60/779,145 2006-03-02
PCT/US2006/026331 WO2007008586A2 (en) 2005-07-08 2006-07-07 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions

Publications (2)

Publication Number Publication Date
BRPI0613358A2 BRPI0613358A2 (pt) 2011-01-04
BRPI0613358A8 true BRPI0613358A8 (pt) 2017-12-26

Family

ID=37637739

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0613358A BRPI0613358A8 (pt) 2005-07-08 2006-07-07 ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência

Country Status (12)

Country Link
US (3) US20070032548A1 (pt)
EP (1) EP1904049B1 (pt)
JP (4) JP2009502745A (pt)
KR (5) KR20130101596A (pt)
CN (2) CN103211807A (pt)
AU (1) AU2006269405B2 (pt)
BR (1) BRPI0613358A8 (pt)
CA (1) CA2614473C (pt)
ES (1) ES2617577T3 (pt)
MX (1) MX336435B (pt)
RU (1) RU2444356C2 (pt)
WO (1) WO2007008586A2 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI120720B (fi) * 2006-06-16 2010-02-15 Neurofood Ab Oy Maitopohjaisia elintarvikkeita, jotka sisältävät keskushermoston lipidejä
WO2008124066A1 (en) 2007-04-05 2008-10-16 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
KR101409115B1 (ko) 2007-06-08 2014-06-17 엘지전자 주식회사 다중 안테나 시스템에서 가중치 정보 전송 방법
WO2009002166A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Improving memory in subjects with mini-mental state examination of 24-26
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
AU2008280806B2 (en) * 2007-07-26 2014-12-11 Phenomenome Discoveries Inc. Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
WO2009055818A1 (en) * 2007-10-25 2009-04-30 Research Foundation Of State University Of New York A spectral biomarker and algorithm for the identification and detection of neural stem and progenitor cells and their use in studying mammalian brains
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CA2704371A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
WO2009057994A1 (en) 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
BRPI0822111B8 (pt) 2007-12-20 2021-05-25 Nutricia Nv composição líquida, e, uso de uma composição líquida
CA2709660C (en) 2008-01-04 2018-06-05 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
WO2009158148A1 (en) * 2008-05-30 2009-12-30 The Trustees Of Columbia University In The City Of New York Methods for diagnosis and treatment of neurodegenerative diseases or disorders
CN104042600A (zh) * 2009-02-02 2014-09-17 帝斯曼知识产权资产有限公司 改善认知功能和降低心率的方法
JP4598162B2 (ja) * 2009-02-05 2010-12-15 パナソニック株式会社 撮像処理装置
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
CN102395366A (zh) * 2009-04-14 2012-03-28 金·尼古拉斯·格林 降低前ADAM10分泌酶和/或β分泌酶水平的方法
CN102438468B (zh) * 2009-04-17 2014-06-04 纳塔克制药有限公司 富含低含量植烷酸的ω-3脂肪酸的组合物
US20110177061A1 (en) 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
US20110082205A1 (en) 2009-10-01 2011-04-07 Panker Cynthia A Docosahexaenoic Acid Gel Caps
AU2010306870B2 (en) * 2009-10-13 2016-08-18 Dsm Ip Assets B.V. Reducing the risk of pathological effects of traumatic brain injury
DK2493296T3 (en) 2009-10-30 2019-04-15 Retrotope Inc REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US10058522B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
WO2012148929A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Disorders implicating pufa oxidation
US10154983B2 (en) * 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
RS53496B1 (sr) * 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
ES2845556T3 (es) 2011-11-01 2021-07-27 Dsm Ip Assets Bv Aceite que contiene ácidos grasos poliinsaturados estable oxidativamente
NO2819649T3 (pt) * 2012-02-29 2018-06-09
JP5986440B2 (ja) * 2012-07-05 2016-09-06 国立医薬品食品衛生研究所長 アルツハイマー病の発症を予測する方法
US20140203176A1 (en) * 2013-01-23 2014-07-24 Dow Agrosciences Llc Systems and methods for real-time sampling and analysis of biomolecules beneath the surface of biological tissue
CN103217463A (zh) * 2013-03-14 2013-07-24 中南大学 一种用于bace1抑制剂筛选的电化学方法
CN105163731B (zh) * 2013-07-10 2017-10-31 狮王株式会社 内服组合物
CN104368002B (zh) * 2014-10-17 2019-01-08 中国人民解放军军事医学科学院毒物药物研究所 用于治疗痴呆或认知功能障碍的联合用药物
WO2016112174A2 (en) * 2015-01-08 2016-07-14 The Trustees Of The University Of Pennsylvania Biomarkers of Sleep Deprivation and Cognitive Impairment
KR20170025977A (ko) * 2015-08-31 2017-03-08 재단법인차세대융합기술연구원 옥시리스 마리나로부터 분리된 신규 화합물
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2017091279A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
EP3383482B1 (en) 2015-11-24 2023-01-04 Massachusetts Institute of Technology Systems for preventing, mitigating, and/or treating dementia
ES2800751T3 (es) * 2016-02-22 2021-01-04 Newtricious Bv Composición para la prevención o tratamiento de enfermedades neurodegenerativas
CA3044440A1 (en) 2016-11-17 2018-05-24 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual stimulation
CN106666745A (zh) * 2016-12-22 2017-05-17 徐晓飞 一种含姜黄素和dha的组合物及应用
CN106617064A (zh) * 2016-12-22 2017-05-10 徐晓飞 一种含姜黄素和ω‑3多不饱和脂肪酸的组合物及其应用
CA3051019A1 (en) 2017-03-06 2018-09-13 Jun Liu Inhibiting or alleviating agent for as-induced damage
US11065288B2 (en) 2017-09-29 2021-07-20 Kinjirushi Co., Ltd. Neuron activator
ES3058718T3 (en) 2017-10-10 2026-03-12 Massachusetts Inst Technology Systems for preventing, mitigating, and/or treating dementia
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
CN115066237A (zh) * 2020-01-03 2022-09-16 生物探索有限公司 用于治疗认知障碍的组合物
EP4107163A4 (en) 2020-02-21 2024-06-19 Retrotope, Inc. PROCESSES FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES
KR102466479B1 (ko) 2020-03-30 2022-11-15 주식회사 뷰브레인헬스케어 타우 단백질 축적 예측 장치 및 이를 이용한 타우 단백질 축적 예측 방법
CN114680336A (zh) * 2020-12-30 2022-07-01 云南汉盟制药有限公司 一种含火麻仁不饱和脂肪酸的滴剂及其制备方法
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
CN112798727B (zh) * 2021-04-09 2021-07-06 宝枫生物科技（北京）有限公司 用于诊断脑白质病变的生物标志物f7及其应用
CN118742299A (zh) * 2022-02-11 2024-10-01 拜奥吉瓦有限责任公司 监测患者对视网膜氧化性疾病治疗反应的方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5408326A (en) * 1993-04-28 1995-04-18 Shell Oil Company Dual-wavelength absorption detector adapted for continuous-flow detection
US5403826A (en) * 1993-05-28 1995-04-04 Abbott Laboratories Nutritional product for persons infected with human immunodeficiency virus
ES2135756T3 (es) 1994-08-16 1999-11-01 Frische Gmbh Procedimiento para la obtencion de productos nativos no solubles en agua a partir de mezclas de sustancias con ayuda de la fuerza centrifuga.
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
BR9710394A (pt) * 1996-07-23 2000-01-11 Nagase Biochemicals Ltda Processo para preparação de ácido docosahexaenóico e ácido docosapentaenóico;processo de preparação a partir de lipidio;microorganismo produtor de lipìdios;alimentos e congenêres abtidos através do processo
AU731692C (en) * 1996-10-11 2001-10-11 Scarista Limited Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6596766B1 (en) * 1999-03-04 2003-07-22 Suntory Limited Utilization of material containing docosapentaenoic acid
CA2311974A1 (en) * 1999-06-28 2000-12-28 Nisshin Flour Milling Co., Ltd. Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
US6395778B1 (en) * 2000-01-11 2002-05-28 Omegatech, Inc. Process for making an enriched mixture of polyunsaturated fatty acid esters
ATE395835T1 (de) 2000-04-12 2008-06-15 Westfalia Separator Gmbh Verfahren zur fraktionierung von öl- und polar lipid-enthaltenden rohstoffen
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
JP4629834B2 (ja) * 2000-05-12 2011-02-09 備前化成株式会社 神経細胞賦活剤およびその利用
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20040106584A1 (en) * 2002-09-27 2004-06-03 Linda Arterburn Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
EP1558237A4 (en) * 2002-09-27 2007-01-17 Martek Biosciences Corp IMPROVED BLOOD SUGAR CONTROL F RPRU-DIABETES AND / OR DIABETES TYPE II USING DOCOSAHEXAENSURE
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US7935365B2 (en) * 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN LACK OR DYSFUNCTION AND RELEVANT PROCEDURE
US20060020031A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
CA2588166A1 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
DE102005003625A1 (de) * 2005-01-26 2006-07-27 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Verfahren zur Herstellung einer DHA-haltigen Fettsäure-Zusammensetzung
US20060270739A1 (en) * 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
JP5337479B2 (ja) * 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
CA2645645C (en) * 2005-05-23 2015-07-14 Massachusetts Institute Of Technology Compositions containing pufa and methods of use thereof
US20070042953A1 (en) * 2005-08-16 2007-02-22 Bazan Nicolas G Antiepileptogenic complex of albumin with docosahexaenoate
US20070053955A1 (en) * 2005-08-26 2007-03-08 Nestec S.A. Compositions and methods for improving cellular survival and reducing apoptosis after ischemic episode in the brain
US20090023808A1 (en) * 2007-06-29 2009-01-22 Martek Biosciences Corporation Production and Purification of Esters of Polyunsaturated Fatty Acids

Also Published As

Publication number Publication date
KR20080027384A (ko) 2008-03-26
US20110218242A1 (en) 2011-09-08
EP1904049A2 (en) 2008-04-02
KR20180026556A (ko) 2018-03-12
MX2008000178A (es) 2008-04-07
CN101262863A (zh) 2008-09-10
EP1904049A4 (en) 2012-08-01
CA2614473A1 (en) 2007-01-18
JP2009502745A (ja) 2009-01-29
ES2617577T3 (es) 2017-06-19
KR101965124B1 (ko) 2019-04-02
JP2013056900A (ja) 2013-03-28
US20070032548A1 (en) 2007-02-08
CA2614473C (en) 2016-05-03
BRPI0613358A2 (pt) 2011-01-04
AU2006269405A1 (en) 2007-01-18
KR101870626B1 (ko) 2018-06-26
JP2015147775A (ja) 2015-08-20
EP1904049B1 (en) 2016-12-07
KR20190014122A (ko) 2019-02-11
KR20160116351A (ko) 2016-10-07
CN101262863B (zh) 2016-08-31
KR20130101596A (ko) 2013-09-13
WO2007008586A3 (en) 2007-04-12
RU2008104697A (ru) 2009-08-20
WO2007008586A2 (en) 2007-01-18
CN103211807A (zh) 2013-07-24
AU2006269405B2 (en) 2013-01-17
RU2444356C2 (ru) 2012-03-10
MX336435B (es) 2016-01-19
US20150119464A1 (en) 2015-04-30
JP2018021078A (ja) 2018-02-08

Similar Documents

Publication Publication Date Title
MX336435B (es) Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.
BRPI0512864A (pt) composições e métodos para o tratamento de condições e desordens oculares
CR9528A (es) Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
MX2009009200A (es) Tratamiento de enfermedades caracterizadas por la inflamacion.
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
DE602007012133D1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
ATE509624T1 (de) Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
BRPI0516645A (pt) composições de perfume
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
DE602006014452D1 (de) Hautbehandlungszusammensetzung
TW200942549A (en) Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
EP4419690A4 (en) USEFUL COMPOSITIONS IN THE TREATMENT OF CDKL5 DEFICIENCY DISORDER (CDD)
EP4210720C0 (en) PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF ACNE
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
EP4096675C0 (en) COMPOSITIONS FOR THE TREATMENT OF LONG COVID
WO2008011178A3 (en) Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DSM IP ASSETS B.V. (NL)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]